The introduction of Retatrutide ZPHC, at a dosage of 120mg, is sparking considerable excitement within the healthcare community. This novel dual GIP and GLP-1 agonist medication seems to deliver impressive improvements in fat loss compared to current therapies. Initial research studies have shown marked declines in body fat percentage, potentially